Roche says U.S. FDA issues Emergency Use Authorization for Zika test
Roche tablets are seen positioned in front of a displayed Roche logo in this photo illustration shot January 22, 2016. REUTERS/Dado Ruvic/Illustration/File Photo
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
ZURICH (Reuters) - Swiss drugmaker Roche (NYSE: ROG) said on Monday the U.S. Food and Drug Administration (FDA) had issued an Emergency Use Authorization (EUA) for its test for the Zika virus.
"The LightMix Zika test is an easy-to-use molecular diagnostic test that enables healthcare professionals to quickly detect the virus," said Uwe Oberlaender, the head of molecular diagnostics at Basel-based Roche.
The virus has been associated with microcephaly, a birth defect characterized by an unusually small head and potential developmental problems.
(Reporting by Joshua Franklin; Editing by Subhranshu Sahu)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer
- FDA Approves Genentech's Avastin Plus Chemotherapy to Treat Type of Ovarian Cancers (RHHBY)
- Russia says U.S. bill will restrict its diplomats, pledges retaliation
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!